Biotech Values

[mcbio]

Re: MNTA/generic Copaxone competition

Quote:
--------------------------------------------------------------------------------
I assume MNTA need only succeed on one of these four arguments. Is that correct?
--------------------------------------------------------------------------------

Yes.
Quote:
--------------------------------------------------------------------------------
…which of the four arguments do you see as holding the best chance for MNTA to succeed?
--------------------------------------------------------------------------------

Obviousness/double patenting, i.e. that the Orange Book patents are obvious extensions of older Copaxone patents.

Thanks Dew. And I apologize in advance if already discussed on the Board, but I don't recall a lot of chatter about the potential competition for MNTA as it relates to generic Copaxone. I assume MYL is potential competition, given their involvement in the Copaxone patent litigation. Who are the other main potential competitors that we know of or expect? And who is the biggest threat? Obviously, TEVA will likely not be competition here, since they have the branded drug in this instance.